3CAI

CAS No. 28755-03-5

3CAI( —— )

Catalog No. M24203 CAS No. 28755-03-5

3CAI is a potent and specific AKT1 and AKT2 inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 45 In Stock
10MG 63 In Stock
25MG 114 In Stock
50MG 209 In Stock
100MG 313 In Stock
200MG 460 In Stock
500MG 746 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    3CAI
  • Note
    Research use only, not for human use.
  • Brief Description
    3CAI is a potent and specific AKT1 and AKT2 inhibitor.
  • Description
    3CAI is a potent and specific AKT1 and AKT2 inhibitor.
  • In Vitro
    3CAI is a potential inhibitor of AKT. Based on these screening data, the effect of 3CAI on the kinase activities of AKT1, MEK1, JNK1, ERK1 and TOPK is tested using in vitro kinase assays. The results show that 3CAI (1 μM) suppresses only AKT1 kinase activity and the other kinases tested are not affected by 3CAI. 3CAI is a much more potent AKT1 inhibitor than PI3K (60% inhibition at 1 vs 10 μM, respectively). 3CAI substantially suppresses AKT1 activity as well as AKT2 activity in a dose dependent manner. 3CAI inhibits down-stream targets of AKT and induces apoptosis. AKT-mediated phosphorlyation site of mTOR (Ser2448) and GSK3β (Ser9) are substantially decreased by 3CAI in a time-dependent manner. Furthermore, pro-apoptotic marker proteins p53 and p21 are also upregulated by 3CAI after 12 or 24 h of treatment. HCT116 and HT29 colon cancer cells are seeded on 6 cm dishes in 1% FBS/McCoy's 5A (HCT116) with 3CAI (4 μM), I3C or the AKT inhibitor and then incubated for 4 days. Results show that the number of apoptotic cells is significantly increased by 3CAI in HCT116 and HT29 colon cancer cells compared with untreated control cells.
  • In Vivo
    To examine the antitumor activity of 3CAI in vivo, HCT116 cancer cells are injected into the right flank of individual athymic nude mice. Mice are orally administered 3CAI at 20 or 30 mg/kg, I3C at 100 mg/kg, or vehicle 5 times a week for 21 days. Treatment of mice with 30 mg/kg of 3CAI significantly suppresses HCT116 tumor growth by 50% relative to the vehicle-treated group (p<0.05). Remarkably, mice seem to tolerate treatment with these doses of 3CAI without overt signs of toxicity or significant loss of body weight compared with vehicle-treated group. Expression of these AKT-target proteins is strongly suppressed by 30 mg/kg of 3CAI in tumor tissues.
  • Synonyms
    ——
  • Pathway
    Cytoskeleton/Cell Adhesion Molecules
  • Target
    Akt
  • Recptor
    Akt1|Akt2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    28755-03-5
  • Formula Weight
    193.63
  • Molecular Formula
    C10H8ClNO
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:246 mg/mL (1270.46 mM; Need ultrasonic)
  • SMILES
    O=C(CCl)c1c[nH]c2c1cccc2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Kim DJ, et al. (3-Chloroacetyl)-indole, a novel allosteric AKT inhibitor, suppresses colon cancer growth in vitro and in vivo. Cancer Prev Res (Phila). 2011 Nov;4(11):1842-51.
molnova catalog
related products
  • Cinobufotalin

    Cinobufotalin is a main cardiac toxin in toad, it is a novel anti-HCC agent, it induces growth inhibition and apoptosis in cultured HCC cells through ceramide production.

  • Vevorisertib trihydr...

    Vevorisertib trihydrochloride (ARQ 751 trihydrochloride) is a selective and potent inhibitor of pan-AKT and AKT1-E17K mutations, inhibiting AKT1, AKT2 and AKT3.

  • Guggulsterone E&Z

    Guggulsterone E&Z?is a 3-hydroxy steroid. It has a role as an androgen.